Drug reference
Mepolizumab
Monoclonal Antibody · treatment for severe refractory eosinophilic asthma
Monoclonal Antibodytreatment for severe refractory eosinophilic asthma
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
Avoid - no information available
FDA category + note
Mechanism
Mepolizumab is a humanised anti-interleukin-5 (anti-IL-5) monoclonal antibody. It reduces the production and survival of eosinophils.
Indications
Add on treatment for severe refractory eosinophilic asthma (under expert supervision)maintenance treatment of severe asthma (eosinophilic phenotype)eosinophilic granulomatosis with polyangiitishypereosinophilic syndromeHypereosinophilic Syndrome (HES) when usual therapy fails
Dosing
- Adult
- 100 mg every 4 weeks by subcutaneous injection
Contraindications
- Helminth infection
Side effects
Common
Minimal side effects reported.
Pregnancy & lactation
Pregnancy
Avoid - no information available
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Mepolizumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-10 · House clinical team